JAK1 and Alzheimer disease: The efficiency of ivarmacitinib (SHR0302), a highly selective JAK-1 inhibitor that presents a mild JAK2-inhibiting effect, has been examined in a randomized, double-blind, placebo-controlled, multicenter, phase 2 trial in patients with moderate to severe AD.